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Novel Mutations Lead to New Genotype/Phenotype Correlations
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and Edward H. Schuchman
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We have collected demographic and/or mutation information on a worldwide sample of 394 patients with type B
Niemann-Pick disease (NPD). The disorder is panethnic, with the highest incidence occurring in individuals of
Turkish, Arabic, and North African descent. Only five of the 394 patients were Ashkenazi Jewish, revealing that,
unlike the type A form of NPD, type B NPD does not occur frequently within this population. Mutation analysis
of the acid sphingomyelinase (ASM) gene (designated “SMPD1”) was performed on 228 patients (324 unique
alleles), and several novel, “common” mutations were found. Among these were the L137P, fsP189, and L549P
mutations, which accounted for ∼75% of the alleles in Turkish patients, the H421Y and K576N mutations, which
accounted for ∼85% of the alleles in Saudi Arabian patients, the S379P, R441X, R474W, and F480L mutations,
which accounted for ∼55% of the alleles in Portuguese/Brazilian patients, and the A196Pmutation, which accounted
for ∼42% of the alleles in Scottish/English patients. The previously reported DR608 mutation occurred on ∼12%
of the alleles studied. Overall, a total of 45 novel mutations were found, and several new genotype/phenotype
correlations were identified. In particular, the L137P, A196P, and R474W mutations were consistent with a less
severe form of type B NPD, whereas the H421Y and K576N mutations led to an early-onset, more severe form
that was specific to Saudi Arabia. These data provide the first extensive demographic assessment of this disorder
and describe several new mutations that can be used to predict phenotypic outcome and to gain new insights into
the structure and function of ASM.
Introduction
Types A and B Niemann-Pick disease (NPD [MIM
257200]) are lysosomal storage disorders resulting from
the deficient activity of acid sphingomyelinase (ASM)
and the subsequent accumulation of sphingomyelin, cho-
lesterol, and other lipids within cells and tissues of af-
fected individuals (Schuchman and Desnick 2001). Pa-
tients with type A NPD are usually diagnosed early in
infancy with organomegaly and follow a rapid neurod-
egenerative course that leads to death by ∼3 years of
age. In contrast, patients with type B NPD have little or
no CNS involvement and often survive into adulthood.
However, the type B form of NPD is clinically hetero-
geneous and can present with a variety of findings that
may include hepatosplenomegaly, growth retardation,
frequent respiratory infections, fatigue, and hematologic
abnormalities such as high levels of LDL cholesterol and
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triglycerides, low levels of HDL cholesterol, and low
numbers of platelets. In addition, several patients with
type B NPD have been reported who had an intermediate
phenotype that included neurodegeneration (see, e.g.,
Elleder and Cihula 1983; Elleder et al. 1986). Both forms
of NPD are panethnic, although most reported cases
of type A NPD occurred among Ashkenazi Jewish
individuals.
The full-length cDNA and genomic sequences encod-
ing human ASM have been isolated (Schuchman et al.
1991, 1992), and a total of 23 mutations causing type
A or B NPD have been published (gene designation
“SMPD1”). Of these, 15 are missense mutations (Fer-
linz et al. 1991; Levran et al. 1991a, 1992; Takahashi
et al. 1992a, 1992b; Schuchman 1995; Schuchman and
Miranda 1997), 2 are nonsense mutations (Schuchman
1995; Schuchman and Miranda 1997), 4 are frameshift
mutations (Levran et al. 1991a, 1993b), and 1 results
from an in-frame 3-bp deletion that results in the re-
moval of a single amino acid from the ASM polypeptide
(Levran et al. 1991b). One splice-site alteration also has
been described (Levran et al. 1993a). Notably, three
common mutations account for 190% of the mutant
alleles in patients of Ashkenazi Jewish ancestry who had
type A NPD (Levran et al. 1991a, 1992, 1993b). Two
are missense mutations, R496L and L302P, and the
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third is a 1-bp deletion that causes a frameshift and the
introduction of a premature stop codon within the ASM
open reading frame (fsP330). The combined carrier fre-
quency for these mutations among Ashkenazi Jewish
individuals is between 1/80 and 1/100 (Li et al. 1997).
Only one other mutation has so far been identified in the
Ashkenazi Jewish population with type A NPD (Schuch-
man 1995); this mutation, designated “N389T,” was
identified as one of the mutant alleles in a single patient
with type A NPD; the other allele was fsP330. In con-
trast to the Ashkenazi Jewish population, each of the
non-Jewish patients with type A NPD studied has had
unique, or “private,” ASM mutations.
The first mutation (designated “DR608”) in a patient
with type B NPD was found in a mildly affected Ash-
kenazi Jewish individual who carried a 3-bp deletion in
exon 6 that predicted the removal of an arginine residue
from position 608 of the ASM polypeptide (Levran et
al. 1991b). This patient carried the R496L mutation on
her other allele, suggesting that the presence of the
DR608 mutation was “neuroprotective.” A second Ash-
kenazi Jewish type B patient was subsequently found to
be heteroallelic for DR608 and a new mutation, des-
ignated “H575L.” In addition to these two patients, the
DR608 mutation was frequently found in North African
patients with type B NPD who originated from the Ma-
ghreb region (i.e., Tunisia, Algeria, and Morocco) (Van-
ier et al. 1993), where it may account for almost 90%
of the mutant alleles. To date, only four other mutations
have been reported in patients with type B NPD (Tak-
ahashi et al. 1992a, 1992b; Vanier et al. 1993).
In this article, we report demographic and/or molec-
ular data on a worldwide sample of 394 patients with
type B NPD. Acid sphingomyelinase mutation analysis
was performed on 228 of these patients, and 45 novel
mutations were identified, including several common
mutations that could be used for genetic screening in
specific populations. In addition, we have identified sev-
eral new genotype/phenotype correlations for this dis-
order that should be useful to genetic counselors, phy-
sicians, and families affected with type B NPD.
Subjects and Methods
Subjects
A total of 394 patients with type B NPDwere included
in this study. Of these, 64 patients were evaluated at the
Mount Sinai Clinical Research Center as part of an on-
going natural history study. Information on the remain-
ing 330 patients was obtained from either the treating
physicians or major diagnostic laboratories throughout
the world. Blood was obtained from 228 of the 394
patients and was used to prepare DNA for mutation
analysis (see below). For inclusion in the study, the di-
agnosis of NPD had to be confirmed by SMPD1 mu-
tation analysis and/or by determining markedly reduced
ASM activity (i.e., !5% of normal) in white blood cells
or cultured skin fibroblasts. Cholesterol loading studies
were performed on a small subset of patients to rule out
type CNPD. Type CNPDwas ruled out in the remaining
patients by demonstrating either SMPD1 mutations or
very low, residual ASM activity. Patients also needed to
be 3 years of age and without evidence of neurode-
generation (to rule out type A NPD).
SMPD1 Mutation Analysis
DNA was prepared from whole blood and was used
for mutation analysis as described elsewhere (Schuch-
man and Miranda 1997). Putative mutations were con-
firmed by sequencing duplicate PCR products, restric-
tion enzyme analysis, and by family studies whenever
possible.
Results
Distribution and Ethnicity of Type B NPD
Information was collected on a worldwide sample of
394 patients with type B NPD. Mutation analysis was
performed on 228 of these patients (see below). No pa-
tients were included in this study unless the diagnosis of
NPD was confirmed by SMPD1 mutation analysis and/
or ASM enzyme testing. The distribution of these pa-
tients by country is shown in figure 1. Of these patients,
87 were residing in the United States or Canada. Other
countries with significant numbers of patients in this
data set were France (100), Germany (38), Tunisia (20),
Brazil (19), Saudi Arabia (18), the United Kingdom (17),
Italy (12), and Turkey (10). In total, patients were iden-
tified in 29 countries. The most common ethnic group
among these type B NPD patients was Turkish, followed
by Arabic and Scottish. Only five of the patients were
Ashkenazi Jewish.
Mutation Analysis and Genotype/Phenotype
Correlations
Mutation analysis was carried out on 228 of the type
B NPD patients (324 unique alleles), leading to the iden-
tification of 45 novel mutations (table 1). Among these
were several “common” mutations that occurred within
specific ethnic groups (table 2), including the L137P,
fsP189, and L549P mutations, which accounted for
∼75% of the alleles among Turkish patients; the H421Y
and K576N mutations, which accounted for ∼85% of
the alleles among Saudi Arabian patients; the S379P,
R441X, R474W, and F480L mutations, which ac-
counted for ∼55% of the alleles among Portuguese/Bra-
zilian patients; and the A196P mutation, which ac-
counted for ∼42% of the alleles among Scottish/English
patients. Overall, the previously reported DR608 mu-
Figure 1 Worldwide distribution of patients with type B NPD.A,Distribution by continent of 394 patients with type BNPD.B,Distribution
by country of patients with type B NPD. The distribution within North America is not shown, but 78 patients were residing in the United
States, and 9 were residing in Canada.
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Table 1
Novel Mutations in the ASM Gene








G21X CrT, nt 61 nt 61
D49V ArT, nt 156 nt 146
C92W CrG, nt 276 nt 276
2:
L137P TrC, nt 409 nt 875
C157R TrC, nt 469 nt 934
fsD169 delG, nt 507 nt 970
W174X GrA, nt 522 nt 986
A196P GrC, nt 586 nt 1051
R200C CrT, nt 598 nt 1063
L225M CrA, nt 673 nt 1138
R228C CrT, nt 682 nt 1147
G232D GrA, nt 695 nt 1160
G245S GrA, nt 733 nt 1198
S248R CrA, nt 744 nt 1209
R289H GrA, nt 866 nt 1331
fsS321 delG, nt 962 nt 1427
P323A CrG, nt 967 nt 1432
P330R CrG, nt 989 nt 1454
A357D CrA, nt 1070 nt 1535
3:
fsF366 insT, nt 1096 nt 2621
R376H GrA, nt 1128 nt 2652
R376L GrT, nt 1128 nt 2652
S379P TrC, nt 1135 nt 2661
fsL380 delC, nt 1140 nt 2663
4:
A413V CrT, nt 1239 nt 2762
H421Y CrT, nt 1261 nt 3014
C431R TrC, nt 1291 nt 3045
L432P TrC, nt 1295 nt 3049
W435C GrC, nt 1305 nt 3059
5:
A452V CrT, nt 1355 nt 3311
G456D GrA, nt 1367 nt 3323
R474W CrT, nt 1420 nt 3376
P475L CrT, nt 1424 nt 3380
F480L CrA, nt 1440 nt 3396
A485V CrT, nt 1454 nt 3410
Y488N TrA, nt 1462 nt 3432
6:
G494S GrA, nt 1480 nt 3603
R496C CrT, nt 1486 nt 3609
H514Q TrG, nt 1542 nt 3665
E515V ArT, nt 1544 nt 3667
fsI530 delA, nt 1589 nt 3702
W533R TrC, nt 1609 nt 3709
L549P TrC, nt 1666 nt 3758
K576N GrC, nt 1728 nt 3840
R600H GrA, nt 1799 nt 3911
R600P GrC, nt 1799 nt 3911
a Numbered according to Schuchman et
al. (1991).
b Numbered according to Schuchman et
al. (1992).
Table 2
Common Type B NPD Mutations in
Specific Ethnic Groups























tation occurred on ∼12% of the NPD alleles studied
(∼20% of the alleles among patients living in North
America and Brazil).
On the basis of these molecular studies, several new
genotype/phenotype correlations were identified. In par-
ticular, the L137P, A196P, and R474W mutations were
associated with a mild disease course (table 3), whereas
the H421Y and K576N mutations were consistent with
an early onset form of type B NPD that led to childhood
death. Several other frame-shift or termination muta-
tions were also found that predicted a severe disease
course when homoallelic or present in combination with
another such “null” mutation (see table 1).
ASM Structure/Function Insights
Several of the novel SMPD1 point mutations revealed
new structure/function insights (table 4). Among these,
the G21X mutation was particularly interesting, since it
occurred before the second in-frame translation start site
in the ASM coding region. There are two in-frame start
codons in the ASM sequence (Schuchman et al. 1991),
and this mutation reveals that the first ATG must be
used in vivo. In addition, the H421Y mutation was in-
teresting, because it occurs within the putative active-
site region of ASM and at a histidine residue that might
be involved in zinc binding (He et al. 1999). There are
also three mutations occurring at cystine residues that
might be involved in intra- or intermolecular disulfide
bond formation (C92W, C157R, and C431R). Two of
these cystine residues are within the saposin domain of
ASM and are conserved among all four of the saposin
polypeptides. Finally, two independent mutations oc-
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Table 3













L137P/L137P 4 14   /
L137P/fsP189 2 20   /
L549/L549 3 5   
fsP189/fsP189 1 3   
H421Y/H421Y 11 5 /  
K576N/K576N 2 6 /  
A196P/A196P 2 37   /
A196P/*b 8 30   /
DR474W/*c 6 18   /
DR608/DR608 9 17   /
DR608/*d 21 19   /
a  p present;  p absent;  p severe; / p mild.
b Heterozygous for one of the following mutations: D49V, C157R, G245S, R289H, R376H,
and C431R.
c Heterozygous for one of the following mutations: fsL260, S379P, A485V, or R496L.
d Heterozygous for one of the following mutations: Q21X, D49V, L225M, G245S, S379P,
R441X, Y446C, P475L R494S, R496L, H575L, or R600H.
Table 4
Structure/Function Analysis of Several ASM Mutations
Residue Structure/Function Implications
G21X Reveals that first in-frame ATG is
functional
C92W May affect disulfide bond forma-
tion; within saposin domain (con-
served aa with saposins A–D)
C157R May affect disulfide bond forma-
tion; within saposin domain (con-
served aa with saposins A–D)
R376H and R376L Within putative sphingomyelin
binding domaina
H421Y Within zinc binding domain; within
putative active site regionb
C431R May affect disulfide bond formation
a Putative sphingomyelin binding domain based on homology
to the sphingomyelin binding protein, lysenin.
b Putative active site region based on homologies to phospho-
lipases C and A2.
curred at R376 (R376H and R376L), a residue that is
within a putative sphingomyelin binding domain and is
conserved between ASM and the sphingomyelin binding
protein, lysenin (Yamaji et al. 1998).
Discussion
Several conclusions can be drawn from the data pre-
sented in this manuscript. First, type B NPD is clearly a
panethnic disorder with a worldwide distribution. Most
of the patients were living in the United States orWestern
Europe, where the enzymatic diagnosis can be readily
obtained, or in countries with high rates of consanguin-
ity, such as Saudi Arabia, Turkey, and Tunisia. However,
patients with type B NPD were identified in 29 different
countries, confirming that it is a disorder affecting many
distinct populations. Of the 394 patients analyzed in this
study, family histories were available for 228. Only 5 of
these patients were Ashkenazi Jewish, revealing that un-
like the type A form of this disorder, type B NPD does
not have an Ashkenazi Jewish predilection. Interestingly,
however, each of these five patients carried one copy of
a common Ashkenazi Jewish type A mutation (L302P,
R496L, or fsP330) in combination with DR608. This is
the same genotype combination found previously in Ash-
kenazi Jewish type B patients (Levran et al. 1991b), and
it is consistent with past “mixing” of Jewish and North
African populations (since DR608 represents almost
90% of the type B NPD alleles in the Maghreb region;
see Vanier et al. 1993). In contrast to the Ashkenazi
Jewish population, in which the disease is quite rare,
more than half (∼54%) of the 228 patients studied who
had type B NPD were of Turkish, Arabic, or North Af-
rican ancestry.
Another observation made apparent from this study
is that the presentation of type B NPD is remarkably
heterogeneous, making its clinical diagnosis particularly
difficult. Most of the referring physicians were working
within specialized metabolic disease centers, although a
significant number were private practice endocrinolo-
gists or cardiologists who were managing the patients
for growth retardation or abnormal plasma lipids, re-
spectively. The diagnosis was often not made for several
years after presentation, and in at least seven docu-
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mented cases type B NPD patients were misdiagnosed
with type 1 Gaucher disease. Two others were misdi-
agnosed with type C NPD. Thus, it is not possible to
accurately estimate the incidence of type B NPD because
many patients remain undiagnosed either because of the
lack of enzyme testing, variability in presenting symp-
toms, and/or lack of knowledge about type B NPD
among the treating physicians.
Mutation analysis was carried out on 228 of the type
B NPD patients. Not surprisingly, within the Turkish
and Saudi Arabian populations there were a small num-
ber of common ASMmutations that accounted for most
of the patients. Three mutations were responsible for
170% of the Turkish NPD alleles, and one mutation
accounted for ∼70% of the alleles in Saudi Arabia. We
also identified a number of type B NPD patients with
Scottish heritage. These patients resided in the United
States, the United Kingdom, or Canada, and all carried
the same point mutation (A196P). Patients carrying at
least one copy of this mutation, even when in combi-
nation with a termination or other presumably “null”
mutation, had an adult form of type B NPD that fol-
lowed a fairly mild course. Thus, likeDR608, the A196P
mutation appears to predict a less severe form of type
B NPD. Similar genotype/phenotype analysis suggest-
ed that three other mutations (L137P, R474W, and
R600H) were also consistent with less severe forms of
type B NPD, but more patients carrying these mutations
will have to be identified and studied for these obser-
vations to be confirmed.
In contrast to these mutations, the H421Y mutation,
which occurred on 170% of the type B NPD alleles in
Saudi Arabia, was predictive of an early onset, severe
form of type B NPD. This is a particularly interesting
mutation, since H421 is conserved in several zinc me-
talloenzymes, including a cGMP specific phosphodies-
terase (Francis et al. 1994), and is also conserved among
the human, mouse, and Caenorhabditis elegans ASM
sequences (Lin et al. 1998). Intriguingly, the C. elegans
sequence in which H421 is conserved is zinc activated,
whereas the other C. elegans ASM sequence is not (Lin
et al. 1998). These observations suggest that H421 is a
critical residue in the ASM active site and that the severe
H421Y mutation may affect ASM function by disrupt-
ing zinc binding. Studies to confirm this observation are
currently underway.
It is also notable that three ASMmutations were iden-
tified at cystine residues, since previous studies using
sulfhydryl reducing reagents had shown that intra- or
intermolecular disulfide bonds were important for ASM
structure and function (He et al. 1999). Indeed, each of
these cystine residues were conserved in both of the C.
elegans ASM sequences, and two (C92 and C157) oc-
curred within the previously identified saposin homol-
ogy domain (Linke et al. 2001). It is also of interest
that the C157R mutation had been previously found in
an ASM cDNA clone obtained from a commercial, pla-
cental cDNA library (Ida et al. 1993). Expression stud-
ies using that cDNA sequence had revealed that this
mutation led to an inactive ASM polypeptide.
Thus, with these data, we report the first extensive
demographic analysis of type B NPD. Forty-five new
ASM mutations were identified, including several com-
mon mutations occurring within specific ethnic groups.
This information should be useful to genetics counsel-
ors, physicians, and/or families who are considering
prenatal testing for NPD and/or genetic screening to
identify carrier individuals. In addition, several new ge-
notype/phenotype correlations were identified. Most
important among these is the fact that patients carrying
at least one copy of the A196P mutation will develop
a less severe form of type B NPD than patients hom-
oallelic for the H421Y mutation, who will develop an
early-onset, severe form of the disease. The identifica-
tion of these new mutations has also provided new
structure/function insights about ASM.
These results also have important implications for
the design of upcoming enzyme-replacement therapy
trials for type B NPD, since several of the mutations
identified (e.g., fsP189 and R441X) are frame-shift or
termination mutations that will likely lead to the pro-
duction of rapidly degraded proteins. Thus, individ-
uals carrying these mutations may experience more
immunologic reactions to the infused enzyme than
those carrying point mutations expressing residual ac-
tivity (e.g., DR608, A196P) (Brooks et al. 1997).
Finally, the data also highlight the fact that type B
NPD remains a disorder that is particularly difficult for
clinicians to diagnose and suggests that screening pro-
grams might be useful in identifying affected patients
who might benefit from future therapies. In this regard,
it might be useful to screen in heart disease clinics for
patients with very low HDL cholesterol levels, since this
is a common finding in almost all patients with type B
NPD, or in endocrinology clinics, where patients may
be seen for growth retardation. The availability of sev-
eral common mutations should facilitate these screening
efforts.
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